Revance Therapeutics, Inc. (NASDAQ:RVNC) Receives $9.66 Consensus PT from Analysts

Revance Therapeutics, Inc. (NASDAQ:RVNC) has earned a consensus recommendation of “Hold” from the nine ratings firms that are covering the company, Marketbeat reports. Eight analysts have rated the stock with a hold rating and one has given a buy rating to the company. The average twelve-month price objective among brokers that have issued a report on the stock in the last year is $9.66.

Several research analysts recently issued reports on the stock. Needham & Company LLC reiterated a “hold” rating on shares of Revance Therapeutics in a research report on Friday, November 8th. Piper Sandler downgraded shares of Revance Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Monday, August 12th. HC Wainwright reissued a “neutral” rating and issued a $6.60 price target on shares of Revance Therapeutics in a research note on Friday, November 8th. William Blair reissued a “market perform” rating on shares of Revance Therapeutics in a research note on Monday, August 12th. Finally, Guggenheim reissued a “neutral” rating on shares of Revance Therapeutics in a research note on Monday, August 12th.

Institutional Investors Weigh In On Revance Therapeutics

Several large investors have recently modified their holdings of the business. Vanguard Group Inc. grew its position in Revance Therapeutics by 6.5% during the 1st quarter. Vanguard Group Inc. now owns 5,398,406 shares of the biopharmaceutical company’s stock worth $26,560,000 after purchasing an additional 328,781 shares during the last quarter. Price T Rowe Associates Inc. MD grew its holdings in shares of Revance Therapeutics by 28.8% in the first quarter. Price T Rowe Associates Inc. MD now owns 69,361 shares of the biopharmaceutical company’s stock valued at $342,000 after purchasing an additional 15,496 shares during the period. California State Teachers Retirement System increased its position in Revance Therapeutics by 9.8% during the first quarter. California State Teachers Retirement System now owns 97,493 shares of the biopharmaceutical company’s stock worth $480,000 after purchasing an additional 8,668 shares during the last quarter. Mirador Capital Partners LP acquired a new stake in Revance Therapeutics during the second quarter worth about $186,000. Finally, RF&L Wealth Management LLC increased its position in Revance Therapeutics by 45.5% during the second quarter. RF&L Wealth Management LLC now owns 48,000 shares of the biopharmaceutical company’s stock worth $123,000 after purchasing an additional 15,000 shares during the last quarter. Institutional investors own 97.70% of the company’s stock.

Revance Therapeutics Trading Down 20.7 %

NASDAQ:RVNC opened at $3.03 on Friday. Revance Therapeutics has a 12 month low of $2.30 and a 12 month high of $9.74. The stock has a market capitalization of $317.85 million, a PE ratio of -1.57 and a beta of 0.82. The firm’s 50 day moving average is $4.73 and its 200 day moving average is $4.48.

Revance Therapeutics (NASDAQ:RVNC) last released its quarterly earnings results on Thursday, November 7th. The biopharmaceutical company reported ($0.37) EPS for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.02). The firm had revenue of $59.88 million for the quarter, compared to analysts’ expectations of $67.73 million. Research analysts predict that Revance Therapeutics will post -1.54 earnings per share for the current year.

Revance Therapeutics Company Profile

Revance Therapeutics, Inc, a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company’s lead drug candidate is DAXXIFY (DaxibotulinumtoxinA-lanm) for injection for the treatment of glabellar lines and cervical dystonia; has completed phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe lateral canthal lines; and has completed Phase II clinical trials for the treatment of adult upper limb spasticity and plantar fasciitis.